ARTICLE | Company News
Novartis buying Ultragenyx’s Priority Review voucher
December 18, 2017 7:52 PM UTC
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) said it will sell its rare pediatric disease Priority Review voucher to Novartis AG (NYSE:NVS; SIX:NOVN) for $130 million. Ultragenyx received the voucher in November, when FDA approved Mepsevii vestronidase alfa-vjbk to treat mucopolysaccharidosis VII (MPS VII; Sly syndrome) (see BioCentury Extra, Nov. 15).
Novartis spokesperson Eric Althoff declined to name the program for which the company intends to use the voucher...